<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-68105</identifier>
<setSpec>0001-6640</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">Psoriasis is a chronic inflammatory skin disorder that affects 2% to 3% of the population. Approximately one-third of the patients note its onset during childhood, and it accounts for 4%of the cutaneous disorders in children. The face and intertriginous areas are often involved, and they are particularly sensitive to the adverse effects of steroid use. Topical calcineurin inhibitors are an effective and safe option for the treatment of inverse psoriasis in children(AU)</dc:description>
<dc:creator>Ciudad Blanco, C</dc:creator>
<dc:creator>Alfageme Roldán, F</dc:creator>
<dc:creator>Hernanz Hermosa, J. M</dc:creator>
<dc:creator>Campos Domínguez, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La psoriasis es una enfermedad crónica inflamatoria de la piel que afecta a un 2-3% de la población general. Aproximadamente, en uno de cada tres pacientes comienza en la edad infantil, y supone el 4% de todas las enfermedades de la piel del niño. La cara y las zonas de los pliegues se ven afectadas con frecuencia, y además son áreas especialmente sensibles a los efectos adversos de los corticoides tópicos. Los inhibidores de la calcineurina tópicos suponen una opción eficaz y segura en el tratamiento de la psoriasis invertida en niños(AU)</dc:description>
<dc:source>Acta Pediatr Esp;66(5): 229-231, mayo 2008. ilus, tab</dc:source>
<dc:identifier>ibc-68105</dc:identifier>
<dc:subject>^d3990^s22016</dc:subject>
<dc:subject>^d30103^s22073</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d3990^s22012</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12002^s22016</dc:subject>
<dc:subject>^d3965</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d2715</dc:subject>
<dc:subject>^d12002^s22067</dc:subject>
<dc:subject>^d4977^s22012</dc:subject>
<dc:subject>^d12225</dc:subject>
<dc:subject>^d10987^s22074</dc:subject>
<dc:subject>^d13255^s22016</dc:subject>
<dc:subject>^d10987^s22066</dc:subject>
<dc:subject>^d10987^s22045</dc:subject>
<dc:subject>^d10987^s22039</dc:subject>
<dc:subject>^d33429^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200805</dc:date>
</metadata>
</record>
</ibecs-document>
